Table 3.
MSI | MSS | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CD8 | CD68 | CD8 | CD68 | |||||||||||||
Low (%) |
High (%) |
Sum | P | Low (%) |
High (%) |
Sum | P | Low (%) |
High (%) |
Sum | P | Low (%) |
High (%) |
Sum | P | |
PD1 | 0.058 | 0.443 | 0.086 | 0.405 | ||||||||||||
Negative | 12(57) | 7(29) | 19 | 4(57) | 15(41) | 19 | 50(61) | 36(47) | 86 | 54(57) | 30(50) | 84 | ||||
Positive | 9(43) | 17(71) | 26 | 3(43) | 22(59) | 25 | 32(39) | 40(53) | 72 | 41(43) | 30(50) | 71 | ||||
Sum | 21(100) | 24(100) | 45 | 7(100) | 37(100) | 44 | 82(100) | 76(100) | 158 | 95(100) | 60(100) | 155 | ||||
PDL1[T] | 1.000 | 0.401 | 0.620 | 0.472 | ||||||||||||
Negative | 14(67) | 16(67) | 30 | 6(86) | 24(65) | 30 | 64(79) | 56(76) | 120 | 74(80) | 44(75) | 118 | ||||
Positive | 7(33) | 8(33) | 15 | 1(14) | 13(35) | 14 | 17(21) | 18(24) | 35 | 19(20) | 15(25) | 34 | ||||
Sum | 21(100) | 24(100) | 45 | 7(100) | 37(100) | 44 | 81(100) | 74(100) | 155 | 93(100) | 59(100) | 152 | ||||
PDL1 | 0.688 | 0.217 | 0.844 | 0.013 | ||||||||||||
Negative | 10(48) | 10(42) | 20 | 5(71) | 15(41) | 20 | 48(59) | 45(61) | 93 | 63(68) | 28(48) | 91 | ||||
Positive | 11(52) | 14(58) | 25 | 2(29) | 22(59) | 24 | 33(41) | 29(39) | 62 | 30(32) | 31(52) | 61 | ||||
Sum | 21(100) | 24(100) | 45 | 7(100) | 37(100) | 44 | 81(100) | 74(100) | 155 | 93(100) | 59(100) | 152 |
GC: gastric cancer; MSI: microsatellite unstable; MSS: microsatellite stable; CD68+ M: CD68+ macrophage; PD1: programmed cell death protein 1; PDL1, programmed death ligand 1; In all 215 cases of gastric cancer, 203 cases immunohistochemical sections were evaluable for PD1 and CD8 simultaneously, 200 cases for PDL1 [T]/PDL1 and CD8 simultaneously, 199 cases for PD1 and CD68 simultaneously, and 196 cases for PDL1 [T]/PDL1 and CD68 simultaneously.